Validation and use of the MM-PBSA approach for drug discovery.
The MM-PBSA approach has become a popular method for calculating binding affinities of biomolecular complexes. Published application examples focus on small test sets and few proteins and, hence, are of limited relevance in assessing the general validity of this method. To further characterize MM-PBSA, we report on a more extensive study involving a large number of ligands and eight different proteins. Our results show that applying the MM-PBSA energy function to a single, relaxed complex structure is an adequate and sometimes more accurate approach than the standard free energy averaging over molecular dynamics snapshots. The use of MM-PBSA on a single structure is shown to be valuable (a) as a postdocking filter in further enriching virtual screening results, (b) as a helpful tool to prioritize de novo design solutions, and (c) for distinguishing between good and weak binders (DeltapIC(50) > or = 2-3), but rarely to reproduce smaller free energy differences.
Kuhn
Bernd
B
Molecular Design, Pharmaceutical Division, F. Hoffmann-La Roche AG, Basel, Switzerland. bernd.kuhn@roche.com
Gerber
Paul
P
Schulz-Gasch
Tanja
T
Stahl
Martin
M
D001665:Binding Sites; D015195:Drug Design; D008024:Ligands; D015394:Molecular Structure; D011485:Protein Binding; D011506:Proteins / Q000737:chemistry*; D021281:Quantitative Structure-Activity Relationship; D012997:Solvents / Q000737:chemistry; D013816:Thermodynamics
D008024:Ligands; D011506:Proteins; D012997:Solvents